Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients

Wang,Bangjun; Lian,Kai; Li,Jun; Mei,Gang

doi:10.3892/etm.2017.5369

Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients

Authors:
- Bangjun Wang
- Kai Lian
- Jun Li
- Gang Mei
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, P.R. China
Published online on: October 24, 2017 https://doi.org/10.3892/etm.2017.5369
Pages: 357-364

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cannabinoid receptor 2 (CNR2) has a critical role in osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). CNR2 expression was found to be downregulated in osteoporotic patients. The present study aimed to investigate the functionality of CNR2 in restoring osteogenic differentiation and mineralization of BMSCs isolated from osteoporotic patients. CNR2 was overexpressed in osteoporotic BMSCs by a lentivirus. Alkaline phosphatase (ALP) activity staining and alizarin red S staining were performed to examine the osteogenic differentiation of osteoporotic BMSCs. Reverse‑transcription quantitative polymerase chain reaction analysis was performed to examine the expression of osteogenic genes in BMSCs. Western blot analysis was used to study the activation of p38 mitogen‑activated protein kinase (MAPK) during osteogenic differentiation of osteoporotic BMSCs after lentivirus‑mediated overexpression of CNR2. The results demonstrated that overexpression of CNR2 in osteoporotic BMSCs increased ALP activity, promoted expression of osteogenic genes and enhanced deposition of mineralized extracellular matrix. In addition, phosphorylation of p38 MAPK was found to be increased by overexpression of CNR2. In conclusion, the present study indicated that restoration of CNR2 recovered the osteogenic differentiation of BMSCs isolated from osteoporotic patients. This finding may provide a novel strategy for a treatment approach for osteoporosis.

View Figures

View References

1	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser. 843:1–129. 1994.PubMed/NCBI
2	Bhutani G and Gupta MC: Emerging therapies for the treatment of osteoporosis. J Midlife Health. 4:147–152. 2013.PubMed/NCBI
3	Han S, Chen JJ and Chen JZ: Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor. Mini Rev Med Chem. 14:426–443. 2014. View Article : Google Scholar : PubMed/NCBI
4	Vasileiou I, Fotopoulou G, Matzourani M, Patsouris E and Theocharis S: Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases. Expert Opin Ther Targets. 17:363–377. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yang P, Wang L and Xie XQ: Latest advances in novel cannabinoid CB (2) ligands for drug abuse and their therapeutic potential. Future Med Chem. 4:187–204. 2012. View Article : Google Scholar : PubMed/NCBI
6	Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA and Ralston SH: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 11:774–779. 2005. View Article : Google Scholar : PubMed/NCBI
7	Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, et al: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 103:pp. 696–701. 2006; View Article : Google Scholar : PubMed/NCBI
8	Sophocleous A, Landao-Bassonga E, Van't Hof R, Ralston S and Idris A: The type 2 cannabinoid receptors (CB2) protects against age-related osteoporosis by affecting bone formation and CB2 agonists exhibit anabolic activity in vivo. Bone. 44:S2192009. View Article : Google Scholar
9	Sun YX, Xu AH, Yang Y, Zhang JX and Yu AW: Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells. Biomed Res Int. 2015:8749822015.PubMed/NCBI
10	Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ and Ralston SH: Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab. 10:139–147. 2009. View Article : Google Scholar : PubMed/NCBI
11	Fernandes H, Dechering K, Van Someren E, Steeghs I, Apotheker M, Leusink A, Bank R, Janeczek K, Van Blitterswijk C and de Boer J: The role of collagen crosslinking in differentiation of human mesenchymal stem cells and MC3T3-E1 cells. Tissue Eng Part A. 15:3857–3867. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wu L, Wu Y, Lin Y, Jing W, Nie X, Qiao J, Liu L, Tang W and Tian W: Osteogenic differentiation of adipose derived stem cells promoted by overexpression of osterix. Mol Cell Biochem. 301:83–92. 2007. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Giusti A and Bianchi G: Treatment of primary osteoporosis in men. Clin Interv Aging. 10:105–115. 2014.PubMed/NCBI
15	Maruotti N, Corrado A, Neve A and Cantatore FP: Bisphosphonates: Effects on osteoblast. Eur J Clin Pharmacol. 68:1013–1018. 2012. View Article : Google Scholar : PubMed/NCBI
16	Russell RG: Bisphosphonates: The first 40 years. Bone. 49:2–19. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rudic JS, Poropat G, Krstic MN, Bjelakovic G and Gluud C: Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev: CD009146. 2011. View Article : Google Scholar
18	Montagnani A and Gonnelli S: Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab. 15:784–791. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lewiecki EM: Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 18:1615–1626. 2009. View Article : Google Scholar : PubMed/NCBI
20	Caplan AI: Mesenchymal stem cells. J Orthop Res. 9:641–650. 1991. View Article : Google Scholar : PubMed/NCBI
21	Dore-Duffy P: Pericytes: Pluripotent cells of the blood brain barrier. Curr Pharm Des. 14:1581–1593. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sousa-Victor P, Garcia-Prat L, Serrano AL, Perdiguero E and Muñoz-Cánoves P: Muscle stem cell aging: Regulation and rejuvenation. Trends Endocrinol Metab. 26:287–296. 2015. View Article : Google Scholar : PubMed/NCBI
23	Carrió E and Suelves M: DNA methylation dynamics in muscle development and disease. Front Aging Neurosci. 7:192015. View Article : Google Scholar : PubMed/NCBI
24	Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, et al: Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci. 32:4004–4016. 2012. View Article : Google Scholar : PubMed/NCBI
25	Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D and Tuma RF: Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J Neurotrauma. 28:2417–2427. 2011. View Article : Google Scholar : PubMed/NCBI